Detection of BCR-ABL1 mutations in chronic myeloid leukaemia by massive parallel sequencing

British Journal of Haematology

Volumn 160, Issue 4, 2013, Pages 477-486

  Eyal, Eran ^a   Tohami, Tali ^a   Amir, Amnon ^a   Cesarkas, Karen ^a   Jacob Hirsch, Jasmine ^a   Volchek, Yuliya ^a   Nagler, Arnon ^a,b   Rechavi, Gideon ^a,b   Amariglio, Ninette ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

BCR ABL1; Chronic myeloid leukaemia; Massive parallel sequencing; Resistance conferring mutation; Single nucleotide variant

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; NILOTINIB;

ADULT; ARTICLE; BCR ABL1 GENE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MALE; MASSIVE PARALLEL SEQUENCING; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

ADULT; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84873084099     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12171     Document Type: Article

References (48)

1. Agrawal, M., Garg, R.J., Kantarjian, H. & Cortes, J. (2010) Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Current Oncology Reports, 12, 302-313.
2. Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., Hochhaus, A., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Radich, J., Simonsson, B., Silver, R.T., Goldman, J. & Hehlmann, R. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27, 6041-6051.
3. Branford, S. & Hughes, T. (2006) Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods in Molecular Medicine, 125, 93-106.
4. Bueno, R., De, R.A., Dong, L., Gordon, G.J., Hercus, C.F., Richards, W.G., Jensen, R.V., Anwar, A., Maulik, G., Chirieac, L.R., Ho, K.F., Taillon, B.E., Turcotte, C.L., Hercus, R.G., Gullans, S.R. & Sugarbaker, D.J. (2010) Second generation sequencing of the mesothelioma tumor genome. PLoS ONE, 5, e10612.
5. Carella, A.M., Garuti, A., Cirmena, G., Catania, G., Rocco, I., Palermo, C., Pica, G., Pierri, I., Miglino, M., Ballestrero, A., Gobbi, M. & Patrone, F. (2010) Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. Leukemia & ymphoma, 51, 275-278.
6. Chin, L., Hahn, W.C., Getz, G. & Meyerson, M. (2011) Making sense of cancer genomic data. Genes & Development, 25, 534-555.
7. Corbin, A.S., La, R.P., Stoffregen, E.P., Druker, B.J. & Deininger, M.W. (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood, 101, 4611-4614.
8. Deininger, M.W. (2008) Milestones and monitoring in patients with CML treated with imatinib. Hematology American Society of Hematology. Education Program, 41, 9-426.
9. Druker, B.J. (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood, 112, 4808-4817.
10. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J. & Lydon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Natural Medicines, 2, 561-566.
11. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. & Larson, R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 2408-2417.
12. Eide, C.A., Adrian, L.T., Tyner, J.W., Mac, P.M., Anderson, D.J., Wise, S.C., Smith, B.D., Petillo, P.A., Flynn, D.L., Deininger, M.W., O'Hare, T. & Druker, B.J. (2011) The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Research, 71, 3189-3195.
13. Ernst, T., Lin, F., White, E.H., La Rosee, P., Lion, T., Mitterbauer-Hohendanner, G., Vandenberghe, P., Zadro, R., Polakova, K.M., Plachy, R., Guldborg Nyvold, C., Lundan, T., Cayuela, J.-M., Lange, T., Muller, M.C., Zoi, K., Andrikovics, H., Tohami, T., Pane, F., Soverini, S., Arruga, F., Eggen, L., Sacha, T., Diamond, J., Talmaci, R., Pajic, T., Colomer, D., Hermanson, M., Oppliger Leibundgut, E., Valk, P.J.M., Ozbek, U., Gerrard, G., Saglio, G., Hochhaus, A. & Cross, N.C.P. (2010) Harmonized testing for BCR-ABL kinase domain mutations in CML: results of a survey and first control round within 28 national laboratories in Europe. Blood (ASH Annual Meeting Abstracts), 116, 894.
14. Gabert, J., Beillard, E., van der Velden, V.H., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J.M., Cavé, H., Pane, F., Aerts, J.L., De Micheli, D., Thirion, X., Pradel, V., González, M., Viehmann, S., Malec, M., Saglio, G. & van Dongen, J.J. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia, 17, 2318-2357.
15. Gambacorti-Passerini, C.B., Gunby, R.H., Piazza, R., Galietta, A., Rostagno, R. & Scapozza, L. (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncology, 4, 75-85.
16. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. & Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
17. Gruber, F.X., Ernst, T., Porkka, K., Engh, R.A., Mikkola, I., Maier, J., Lange, T. & Hochhaus, A. (2012) Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia, 26, 172-177.
18. Hanfstein, B., Muller, M.C., Kreil, S., Ernst, T., Schenk, T., Lorentz, C., Schwindel, U., Leitner, A., Hehlmann, R. & Hochhaus, A. (2011) Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica, 96, 360-366.
19. Hirst, M. & Marra, M.A. (2010) Next generation sequencing based approaches to epigenomics. Briefings in Functional Genomics, 9, 455-465.
20. Hochhaus, A. & La Rosée, P. (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia, 18, 1321-1331.
21. Ingolia, N.T. (2010) Genome-wide translational profiling by ribosome footprinting. Methods in Enzymology, 470, 119-142.
22. Ingolia, N.T., Ghaemmaghami, S., Newman, J.R. & Weissman, J.S. (2009) Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science, 324, 218-223.
23. Jabbour, E., Kantarjian, H.M., Jones, D., Shan, J., O'Brien, S., Reddy, N., Wierda, W.G., Faderl, S., Garcia-Manero, G., Verstovsek, S., Rios, M.B. & Cortes, J. (2009) Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood, 113, 2154-2160.
24. Khorashad, J.S., Milojkovic, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A.G., de Melo, V., Babb, A., de Lavallade, H., Olavarria, E., Marin, D., Goldman, J.M., Apperley, J.F. & Kaeda, J.S. (2008) In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood, 111, 2378-2381.
25. Khorashad, J.S., Kelley, T., Szankasi, P., Adrian, L., Eide, C., Zabriskie, M., Lange, T., Kraft, I., Eiring, A., O'Hare, T. & Deininger, M. (2011) Frequency and clonality of BCR-ABL compound mutations in chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts), 118, 3744.
26. Ley, T.J., Mardis, E.R., Ding, L., Fulton, B., McLellan, M.D., Chen, K., Dooling, D., Dunford-Shore, B.H., McGrath, S., Hickenbotham, M., Cook, L., Abbott, R., Larson, D.E., Koboldt, D.C., Pohl, C., Smith, S., Hawkins, A., Abbott, S., Locke, D., Hillier, L.W., Miner, T., Fulton, L., Magrini, V., Wylie, T., Glasscock, J., Conyers, J., Sander, N., Shi, X., Osborne, J.R., Minx, P., Gordon, D., Chinwalla, A., Zhao, Y., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M., Baty, J., Ivanovich, J., Heath, S., Shannon, W.D., Nagarajan, R., Walter, M.J., Link, D.C., Graubert, T.A., DiPersio, J.F. & Wilson, R.K. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456, 66-72.
27. Lowenberg, B. (2003) Minimal residual disease in chronic myeloid leukemia. New England Journal of Medicine, 349, 1399-1401.
28. Ma, W., Kantarjian, H., Jilani, I., Gorre, M., Bhalla, K., Ottmann, O., Giles, F. & Albitar, M. (2006) Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia, 20, 1989-1991.
29. Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Locke, D.P., Magrini, V.J., Abbott, R.M., Vickery, T.L., Reed, J.S., Robinson, J.S., Wylie, T., Smith, S.M., Carmichael, L., Eldred, J.M., Harris, C.C., Walker, J., Peck, J.B., Du, F., Dukes, A.F., Sanderson, G.E., Brummett, A.M., Clark, E., McMichael, J.F., Meyer, R.J., Schindler, J.K., Pohl, C.S., Wallis, J.W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M.E., Ivy, J.V., Kalicki, J., Elliott, G., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M.A., Baty, J., Heath, S., Shannon, W.D., Nagarajan, R., Link, D.C., Walter, M.J., Graubert, T.A., DiPersio, J.F., Wilson, R.K. & Ley, T.J. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine, 361, 1058-1066.
30. Nowell, P. & Hungerford, D. (1960) A minute chromosome in chronic granulocytic leukemia. Science, 132, 1497-1501.
31. Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C. & Ferrin, T.E. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25, 1605-1612.
32. Pleasance, E.D., Cheetham, R.K., Stephens, P.J., McBride, D.J., Humphray, S.J., Greenman, C.D., Varela, I., Lin, M.L., Ordonez, G.R., Bignell, G.R., Ye, K., Alipaz, J., Bauer, M.J., Beare, D., Butler, A., Carter, R.J., Chen, L., Cox, A.J., Edkins, S., Kokko-Gonzales, P.I., Gormley, N.A., Grocock, R.J., Haudenschild, C.D., Hims, M.M., James, T., Jia, M., Kingsbury, Z., Leroy, C., Marshall, J., Menzies, A., Mudie, L.J., Ning, Z., Royce, T., Schulz-Trieglaff, O.B., Spiridou, A., Stebbings, L.A., Szajkowski, L., Teague, J., Williamson, D., Chin, L., Ross, M.T., Campbell, P.J., Bentley, D.R., Futreal, P.A. & Stratton, M.R. (2010a) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature, 463, 191-196.
33. Pleasance, E.D., Stephens, P.J., O'Meara, S., McBride, D.J., Meynert, A., Jones, D., Lin, M.L., Beare, D., Lau, K.W., Greenman, C., Varela, I., Nik-Zainal, S., Davies, H.R., Ordonez, G.R., Mudie, L.J., Latimer, C., Edkins, S., Stebbings, L., Chen, L., Jia, M., Leroy, C., Marshall, J., Menzies, A., Butler, A., Teague, J.W., Mangion, J., Sun, Y.A., McLaughlin, S.F., Peckham, H.E., Tsung, E.F., Costa, G.L., Lee, C.C., Minna, J.D., Gazdar, A., Birney, E., Rhodes, M.D., McKernan, K.J., Stratton, M.R., Futreal, P.A. & Campbell, P.J. (2010b) A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature, 463, 184-190.
34. Preuner, S., Denk, D., Frommlet, F., Nesslboeck, M. & Lion, T. (2008) Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR). Leukemia, 22, 1956-1961.
35. Preuner, S., Mitterbauer, G., Mannhalter, C., Herndlhofer, S., Sperr, W.R., Valent, P. & Lion, T. (2012) Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. European Journal of Cancer, 48, 233-236.
36. Qin, Y., Chen, S., Jiang, B., Jiang, Q., Jiang, H., Li, J., Li, L., Lai, Y., Liu, Y. & Huang, X. (2011) Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Annals of Hematology, 90, 47-52.
37. Sayle, R.A. & Milner-White, E.J. (1995) RASMOL: biomolecular graphics for all. Trends in Biochemical Sciences, 20, 374.
38. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J. & Sawyers, C.L. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2, 117-125.
39. Shah, S.P., Morin, R.D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., Delaney, A., Gelmon, K., Guliany, R., Senz, J., Steidl, C., Holt, R.A., Jones, S., Sun, M., Leung, G., Moore, R., Severson, T., Taylor, G.A., Teschendorff, A.E., Tse, K., Turashvili, G., Varhol, R., Warren, R.L., Watson, P., Zhao, Y., Caldas, C., Huntsman, D., Hirst, M., Marra, M.A. & Aparicio, S. (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature, 461, 809-813.
40. ™) sequencing sensitively detects polyclonal and compound BCR-ABL in patients who relapse on kinase inhibitor therapy. 53th ASH Annual Meeting and Exposition. Blood (ASH Annual Meeting Abstracts), 118, 3752.
41. Soverini, S., Martinelli, G., Amabile, M., Poerio, A., Bianchini, M., Rosti, G., Pane, F., Saglio, G. & Baccarani, M. (2004) Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clinical Chemistry, 50, 1205-1213.
42. Soverini, S., Vitale, A., Poerio, A., Gnani, A., Colarossi, S., Iacobucci, I., Cimino, G., Elia, L., Lonetti, A., Vignetti, M., Paolini, S., Meloni, G., di Maio., V., Papayannidis, C., Amabile, M., Guarini, A., Baccarani, M., Martinelli, G. & Foa', R. (2011a) Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica, 96, 552-557.
43. Soverini, S., Hochhaus, A., Nicolini, F.E., Gruber, F., Lange, T., Saglio, G., Pane, F., Muller, M.C., Ernst, T., Rosti, G., Porkka, K., Baccarani, M., Cross, N.C. & Martinelli, G. (2011b) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 118, 1208-1215.
44. Stephens, P.J., McBride, D.J., Lin, M.L., Varela, I., Pleasance, E.D., Simpson, J.T., Stebbings, L.A., Leroy, C., Edkins, S., Mudie, L.J., Greenman, C.D., Jia, M., Latimer, C., Teague, J.W., Lau, K.W., Burton, J., Quail, M.A., Swerdlow, H., Churcher, C., Natrajan, R., Sieuwerts, A.M., Martens, J.W., Silver, D.P., Langerod, A., Russnes, H.E., Foekens, J.A., Reis-Filho, J.S., van't Veer, L., Richardson, A.L., Borresen-Dale, A.L., Campbell, P.J., Futreal, P.A. & Stratton, M.R. (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature, 462, 1005-1010.
45. US Patent 20100029676. United States Patent Application 20100029676-T315a and F317i mutations of Bcr-Abl kinase domain. US Patent 20100029676. 2011
46. Vivante, A., Amariglio, N., Koren-Michowitz, M., Shur-Fabian, O., Nagler, A., Rechavi, G. & Cohen, Y. (2007) High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. Leukemia, 21, 1318-1321.
47. Willis, S.G., Lange, T., Demehri, S., Otto, S., Crossman, L., Niederwieser, D., Stoffregen, E.P., McWeeney, S., Kovacs, I., Park, B., Druker, B.J. & Deininger, M.W. (2005) High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood, 106, 2128-2137.
48. Wong, K.M., Hudson, T.J. & McPherson, J.D. (2011) Unraveling the genetics of cancer: genome sequencing and beyond. Annual Review of Genomics and Human Genetics, 12, 407-430.